Beike Biotechnology Opens World's Largest Stem Cell Storage and Processing Facility

Wednesday, May 12, 2010 Genetics & Stem Cells News
Email Print This Page Comment bookmark
Font : A-A+

TAIZHOU, China, May 11 Beike Biotechnology Co. Ltd.,one of the world's leading biotechnology companies focusing on adult stem celltherapies, and the Jiangsu government's China Medical City (CMC) openedChina's state-of-the-art stem cell storage and processing facility today. The20,000 square-meter Stem Cell Regenerative Medicine Industrial Project ofNational Bio-Industry Base (NBPD) houses China's first comprehensiveregenerative medicine technology center and its largest international stemcell bank.

The Stem Cell Regenerative Medicine Industrial Facility gives Beike thecapacity to store and process 1 million copies of stem cells, making it thelargest and most sophisticated stem cell processing center of its kind in theworld. The visionary leadership of the Jiangsu Government and Beike set thestage for this advancement when the partnership broke ground on the projectone year ago. The NBPD facility is part of multi-stage project that consistsof industry partnerships designed to provide a central research zone forChina's regenerative medicine and bio-medical industry. Groups collaboratingon this biotechnology incubation center include those from Fudan University,Huazhong Science and Technology University, Nanjing University Medical School,Jiangsu University, Shanghai Jiao Tong University and Jiangsu ProvincialPeople's Hospital.

"Stem cells are the crown jewel of medical research," said Dr. Ying Song,the center's newly appointed VP for Medical, Scientific and Regulatory Affairs."We are honored China Medical City has chosen Beike as a partner to supportChina's role as a world leader in stem cell technology. Scientists all overthe world -- not just in China but in places like the U.S. and other developedWestern countries -- are engaged in the same work we are here in China MedicalCity. We believe our work will serve as a model for them as we conduct thisimportant research designed to bring life-changing stem cell therapies topatients."

Dr. Song described the mission of the new center as aggressive developmentof new, patented stem cell therapies along with the development of processesand protocols that follow stringent implementation of international qualitybenchmarks. He noted the center will have three main goals: adult stem cellcollection and storage, establishment of processes and protocols based oninternational standards such as the American Association of Blood Banks (AABB),the Foundation for the Accreditation of Cellular Therapy (FACT) standards andISO9001 certifications, and to patent and bring stem cell therapies toclinical practice.

Dr. Shengqin Ye, CEO of Jiangsu Beike Biotech, said Beike's recruitment ofthe world-renowned cyropreservation scientist, Dr. Ying Song, to serve as thecenter's Chief Scientific Officer is evidence of Beike's commitment to qualityand safety. Dr. Ye said, "We are very pleased to have Dr. Song leading thecharge to establish rigorous quality system and stem cell industrializationspecifications. Dr. Song's wide breadth of expertise and experience in theUnited States are key assets as Beike refines stem cell banking protocols andconducts clinical trials."

In addition to his quality management and banking/tissue efforts, Dr.Song's work with Beike includes oversight and coordination of the company'sR&D and publications. Prior to joining Beike, Dr. Song was ScientificDirector of Xytex Research Inc., and Clinical Associate Professor in theDepartment of Surgery and Institute of Molecular Medicine and Genetics, at theMedical College of Georgia, in the United States. Dr. Song also managedsurgery programs for the U.S. South Carolina based Organ Recovery Systems Inc.He earned his M.D. at Xuzhou Medical College, China, in 1983 and his Ph.D. inbiophysics at the Medical Research Council, United Kingdom, in 1992. Dr. Songis extensively published in the fields of vitrification and tissue engineering,and is currently a member of the Editorial Board of Cryobiology.

The expansion of the Jiangsu Stem Cell Bank allows Beike to take anintegrated approach to the development of stem cell therapies. The facilityallows Beike's scientists and physicians to produce the highest quality stemcell therapies available in the world by providing processing, storage, andclinical application development within an amalgamated and efficient framework.

Qian Ling, Director of the Management Committee of China Medical City(CMC), noted, "The grand opening of the largest stem cell management center inthe world; the Jiangsu Beike Biotech Stem Cell Bank here in the CMC,solidifies the CMC's position as a world center for biotechnology andregenerative medicine. Supremacy in all aspects of stem cell management andresearch is the foundation for our successful biotechnology developmentstrategy."

About Beike Biotechnology Company Limited

Beike Biotechnology ( ) is China's leadingbiotechnology company focusing on adult stem cell therapies. Beike'sscientists have been focused on the development and commercialization of adultstem cell therapies since 1999. The company currently produces a full line ofstem cell products from umbilical cord, cord blood, and bone marrow stem cells.Beike's stem cell therapies are administered by physicians at many leadinghospitals throughout China.

Beike's unique processing technologies prepare the cells for use intreating a variety of serious medical conditions including ataxia, braininjury, cerebral palsy, diabetic foot disease, lower limb ischemia, multiplesclerosis, muscular dystrophy, spinal cord injury and optic nerve pathologies.

About China Medical City

Located on a 25-square kilometer site in the heart of Taizhou City inChina's Jiangsu Province, China Medical City was established by the ChineseGovernment in 2005 and has active support from the local government. Itrepresents China's goal of streamlining the pharmaceutical and medicalmaterials industry by concentrating all medical services and support in onecentral location. The city of Taizhou is fast becoming Jiangsu's leadingbiotech location, with over 35% annual growth since 2004. Jiangsu Province ishome to the largest concentration of China's medical industry, based on therevenue generated over the past five years.For more information, please contact: Shenzhen Beike Biotechnology Company, Ltd. T. Gutmann Shenzhen Hi-Tech Industrial Park Tel: +86-755-8630-9200 Email: Web:

SOURCE Beike Biotechnology Company Limited

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store